A physician may consider several maintenance pathways: Continuing the current medication and dose if it is effective and well tolerated
Incorporating patient-specific factors, including genetic markers, metabolic profiles, and patterns of albuminuria, can facilitate earlier detection, improve prognostic accuracy and enable more precise selection of therapeutic interventions, moving clinical practice towards individualized management strategies [34,35,36,37]
The medication is introduced gradually, starting at the lowest dose, and your body needs time to adjust to minimize side effects
After weighting, the only significant difference in baseline characteristics between the semaglutide and DPP-4i groups was in the unknown geographic region category (Table S2)
The uracil rings of both inhibitors induce a conformational change at Tyr547 of subsite S1'
Current BPC-157 users who are adding GLP-1 therapy and want to confirm the two are compatible